Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Conditions: Obesity; Knee Osteoarthritis; Osteoarthritis, Knee Interventions: Drug: Tirzepatide; Drug: Placebo Sponsors: University of Melbourne; Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials